Clinical trial
A Phase 2b, Randomized, Controlled Double-blind, Multicenter Study Comparing the Efficacy and Safety of Zetomipzomib (KZR-616) 30 mg or 60 mg With Placebo in Patients With Active Lupus Nephritis
NCT05781750 is registered in ClinicalTrials.gov with Kezar Life Sciences, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2b, Randomized, Controlled Double-blind, Multicenter Study Comparing the Efficacy and Safety of Zetomipzomib (KZR-616) 30 mg or 60 mg With Placebo in Patients With Active Lupus Nephritis
- Lead sponsor
- Kezar Life Sciences, Inc.
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- November 3, 2023
- Completion date
- November 8, 2024
- Enrollment
- 84 (actual)
- Sites
- 50
Conditions
As the registry lists them; a condition with its own page is linked.